The pharmacokinetics of S H‐methotrexate were studied in 22 patients with malignancies. Search for other works by this author on:

Thus, drug-drug interactions through the transporters and their genetic polymorphisms may alter the PK and PD of MTX, resulting in an interpatient variability of efficacy. 2013 Sep;40(9):1519-22. doi: 10.3899/jrheum.130066. The mechanism for this difference is unclear, but may be related to differences in the carrier-mediated absorption mechanism. The maintenance therapy regimen included daily oral mercaptopurine (75 mg/mThe bioavailability of oral MP is limited by extensive first-pass metabolism of the drug by xanthine oxidase in the liver and intestinal mucosa and averages less than 20%.This substantial degree of pharmacokinetic variability resulting from oral administration of MTX and MP has prompted a number of studies that have attempted to define a relationship between pharmacokinetic parameters and disease outcome. The pharmacokinetics (PK) and pharmacodynamics (PD) of MTX entirely depends on the function of specific transporters that belong to the two major superfamilies, solute carrier transporters and ATP-binding cassette transporters. Search for other works by this author on: The correlation coefficients (Scattergram relating dose to AUC for all monitored doses of oral MTX (A) and MP (B).

Several transporters have been identified as being able to mediate the transport of MTX, and suggested to be involved in the disposition in the body and in the regulation of intracellular metabolism in target cells, together with several enzymes involved in folate metabolism. Methotrexate (MTX) is a derivative of folic acid (folate) and commonly used as an anchor drug for the treatment of rheumatoid arthritis (RA).

Either the most recent measured value or the mean of all previous values for each patient was used, and these variables were assessed as continuous variables and split into two groups (above and below the median value). Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia.Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia.Serum profiles of methotrexate after its administration in children with acute lymphoblastic leukaemia.Methotrexate: Bioavailability and pharmacokinetics.Clinical pharmacology of intermediate-dose oral methotrexate.Oral 6-mercaptopurine in childhood leukemia: Parent drug pharmacokinetics and active metabolite concentrations.Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia.The pharmacology of orally administered chemotherapy.The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia.Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy.Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia.Childhood leukæmia: A relationship between intracellular 6-mercaptopurine metabolites and neutropenia.Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia.Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Childrens Cancer Group phase III trial.Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: A Childrens Cancer Group Study.Enzymatic assay for methotrexate in serum and cerebrospinal fluid.Phase I and clinical pharmacologic study of mercaptopurine administered as a prolonged intravenous infusion.A rapid and sensitive high-performance liquid chromatographic assay for 6-mercaptopurine metabolites in red blood cells.The effect of methotrexate on the bioavailability of oral 6-mercaptopurine.Variable mercaptopurine metabolism in children with leukæmia: A problem of compliance?Copyright © 1998 The American Society of Hematology Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats Methotrexate (MTX) is an anchor drug used to treat rheumatoid arthritis (RA), but responsiveness is variable in effectiveness and toxicity. This report is focused on an evaluation of the pharmacokinetics and pharmacodynamics of MTX in the first 3 months of therapy. 2020 Jul 3;11:1004. doi: 10.3389/fphar.2020.01004. Blits M, Jansen G, Assaraf YG, van de Wiel MA, Lems WF, Nurmohamed MT, van Schaardenburg D, Voskuyl AE, Wolbink GJ, Vosslamber S, Verweij CL.Arthritis Rheum.